Adagio Medical Details Past $19M PIPE Financing, Board Elections, and Executive Compensation

summarizeSummary

Adagio Medical Holdings, Inc. filed its definitive proxy statement for its annual meeting, detailing past significant PIPE financings, executive and director compensation for 2025, and proposals for director elections and auditor ratification.

check_boxKey Events

• Annual Meeting Scheduled

  The company will hold its Annual Meeting of Stockholders on June 16, 2026, to elect two Class II directors and ratify the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm.

• Detailed Past Financings Disclosed

  The filing provides comprehensive details on the 2025 PIPE Financing, which raised approximately $19 million in gross proceeds, and other significant financings from 2024. This includes specific investor participation and the structure of shares, pre-funded warrants, and milestone warrants, offering crucial context for the company's financial runway given its 'going concern' status.

• Executive and Director Compensation for 2025

  The proxy statement outlines the 2025 compensation for named executive officers, including CEO Todd Usen ($2.5M total) and CFO Deborah Kaster ($836k total), as well as compensation for non-employee directors, comprising cash retainers and equity awards.

• Potential Dilution from Equity Plans

  As of December 31, 2025, there are 5,785,552 shares underlying outstanding options and 7,489,261 shares available for future issuance under equity compensation plans, indicating significant potential future dilution.

auto_awesomeAnalysis

This definitive proxy statement provides comprehensive details on Adagio Medical's corporate governance, including the upcoming election of two Class II directors and the ratification of its independent auditor. Crucially, the filing offers an in-depth look at past capital raises, specifically the 2025 PIPE Financing which generated approximately $19 million in gross proceeds, and other financings from 2024. For a company operating under a 'going concern' warning, the detailed disclosure of these substantial capital infusions, including the participation of major institutional investors, provides critical context for understanding the company's financial stability and runway. While these financings are historical, their detailed presentation in this filing is highly relevant for investors assessing the company's ability to secure funding and its current capital structure. The filing also outlines executive and non-employee director compensation for 2025 and details the potential dilution from outstanding equity awards and shares available under incentive plans.